Zepbound

News

Eli Lilly has enlisted the aid of Tan France of US makeover show Queer Eye to change the narrative about obesity in a new campaign.

News

The pricing agreement between Novo Nordisk and Eli Lilly and the Trump administration on GLP-1 drugs for diabetes and obesity has arrived.

News

Eli Lilly is celebrating a massive 54% increase in its third-quarter revenues to $17.6 billion, driven by its medicines for diabetes and obesity.

News

European doctors have said GLP-1 drugs are so effective in obesity that they should be the first choice drug treatment in almost all cases.

News

A triple dose of Novo Nordisk's GLP-1 agonist Wegovy has shown improved activity on weight loss in an obesity trial versus the current formulation.

News

Novo Nordisk and Eli Lilly's GLP-1s offer big health benefits and are cost-effective at current US prices, but affordability remains an issue.